J-FORCE study: A randomized, double-blind, placebo-controlled phase III study evaluating olanzapine (5 mg) combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based, highly emetogenic chemotherapy

詳細情報 詳細情報について

• CRID

  1872272493053344384

• DOI

  10.1093/annonc/mdx388.064

• ISSN

  09237534

• データソース種別

  • OpenAIRE